Cart
sales@molnova.com
PCI-32765 racemate
CAS No. 936563-87-0
PCI-32765 racemate( Ibrutinib Racemate | PCI32765 Racemate | PCI 32765 Racemate )
Catalog No. M16704 CAS No. 936563-87-0
A potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 235 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePCI-32765 racemate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM.
-
DescriptionA potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM; modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.Blood Cancer Approved.
-
In Vitro——
-
In Vivo——
-
SynonymsIbrutinib Racemate | PCI32765 Racemate | PCI 32765 Racemate
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number936563-87-0
-
Formula Weight440.4971
-
Molecular FormulaC25H24N6O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
-
Chemical Name2-Propen-1-one, 1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Honigberg LA, et al. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.
2. Herman SE, et al. Blood. 2014 May 22;123(21):3286-95.
3. Kohrt HE, et al. Blood. 2014 Mar 20;123(12):1957-60.
molnova catalog
related products
-
Tirabrutinib
A potent, selective, third-generation irreversible inhibitor of mutant EGFR.
-
BIIB068
BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM).
-
BDTX-189
BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.
